INTRODUCTION {#s1}
============

Esophageal cancer (EC) is the sixth leading cause of cancer-related mortality worldwide resulting in more than 400,000 deaths annually \[[@R1]\]. A lack of effective chemotherapeutic approaches available to treat patients with EC combined with the fact that many EC patients are diagnosed at advanced stages both contribute to the poor prognosis of this disease \[[@R2]\]. Based on histologic criteria, EC is separated into two major types: esophageal squamous cell cancer (ESCC) and esophageal adenocarcinoma (EAC). ESCC accounts for approximately 90% of EC worldwide \[[@R3]\], which is the main subtype in China and ESCC is the third most commonly diagnosed cancer among men, while the fifth among women \[[@R4]\].

In recent years, studies that comprehensively characterized the genomic landscape of ESCC and EAC have led to an important understanding of the genetic basis of EC and identified genes associated with the pathogenesis of the specific EC subtypes \[[@R5]-[@R9]\]. EAC and ESCC represent distinct disease entities, which may benefit from different therapeutic strategies. Despite advances in personalized treatment of EAC \[[@R10], [@R11]\], effective targeted therapies for ESCC have remained elusive. Fibroblast growth factor receptor 1 (*FGFR1*) amplification is one of the most promising findings in ESCC genomic studies due to the availability of FGFR inhibitors and its association with response to FGFR inhibitor treatment \[[@R12], [@R13]\].

The FGFR tyrosine kinase family consists four kinases: *FGFR1*, *FGFR2*, *FGFR3*, and *FGFR4* and the ligands comprise 22 family members (fibroblast growth factors, FGFs). FGFRs share structural homology with many pharmacologic therapeutic targets, such as vascular endothelial growth factor receptors (VEGFRs) and platelet-derived growth factor receptors (PDGFRs) \[[@R14]\]. Receptor activation by FGFs initiates a series of intracellular events that activates major survival and proliferative signal pathways, and then regulate many biologic processes including the wound repair, formation of new blood vessels, and embryonic development \[[@R15]\]. More recently, increasing evidence demonstrated that FGFRs play crucial roles in cancer development. FGFRs are deregulated by amplification, point mutation, or translocation and amplification is the most common deregulation form in multiple cancer types \[[@R16]-[@R18]\]. Amplification of *FGFR1* has been reported in 13%-22% squamous cell lung cancer \[[@R13], [@R19], [@R20]\], 20% breast cancer \[[@R12], [@R21]\], 10%-17% head and neck squamous cell carcinoma \[[@R22], [@R23]\], and 26.9% malignant peripheral nerve sheath tumor \[[@R24]\]. *FGFR1* amplification induced a strong *FGFR1* dependency that could be exploited therapeutically, and *in vivo* studies have demonstrated inhibition of the *FGFR1* pathway with FGFR inhibitors that led to significant tumor shrinkage \[[@R13], [@R25]\], and translational clinical trials are undertaken \[[@R26]\].

As the significant clinical value of *FGFR1*, the prevalence and the prognostic value of *FGFR1* amplification in ESCC is urgently needed to explore. Some researchers have reported that *FGFR1* amplification rate, ranging from 6% to 9.7%\[[@R27]-[@R29]\]. However, the prognostic value of *FGFR1* amplification is not consistent in different studies. Kim et al \[[@R27]\] recently reported high *FGFR1* amplification is an independent poor prognostic factor and a potential therapeutic target in ESCC. In another study \[[@R28]\] on Caucasian patients, there was no association between *FGFR1* amplification status and clinical outcome. Therefore, further detailed analysis is needed to investigate the prognostic significance of *FGFR1* amplification in ESCC.

In present study, we analyzed *FGFR1* amplification status in 506 ESCC patients with surgically resected and searched for correlations between *FGFR1* amplification and clinicopathological parameters. We meticulously explored the prognostic value of *FGFR1* amplification in these patients with the purpose of precisely predicting patients' outcome.

RESULTS {#s2}
=======

Patient characteristics {#s2_1}
-----------------------

A total of 506 ESCC patients who underwent curative esophagectomy were enrolled (Figure [1](#F1){ref-type="fig"}) in our analysis and the clinical characteristics were listed in Table [1](#T1){ref-type="table"}. There were 415 males and 91 females with a median age of 61.2 years (range 34-83). By anatomic site, 29 were in the upper esophagus, 238 in the middle and 239 in the lower area. A total of 111 tumors had invaded to the mucous layer or submucosa, 224 to the muscularis propria and 171 to the adventitia. Most of the tumor differentiation was grade II (55.7%), 40.1% was grade III, and only 4.2% was grade I. A total of 183 tumors were examined with nerve infiltration, 110 with vessel involvement, 244 with lymph node metastases, and 59 with distant metastases.

![Patients and sample selection flow chart\
Cases with ESCC were identified retrospectively and re-reviewed. Patients whose paraffin-embedded tissue is limited, patients with neoadjuvant therapy, and those with incomplete clinicopathological information or survival information were excluded. Representative tissue blocks were selected, Tissue microarray (TMA) construction was undertaken, and hematoxylin-eosin staining was performed. Patients with limited tumor tissue (less than 100 tumor nuclei) in TMA were excluded. Fluorescent in situ hybridization for *FGFR1* was undertaken. The final cohort of ESCC patients consisted of 506 cases.](oncotarget-08-74539-g001){#F1}

###### Clinicopathological characteristics of the 506 patients with ESCC

  Characteristics         All patients   Patients with Stage I-II disease   Patients with DFS time≥30months   Patients with DFS time≥30months in stage I-II                       
  ----------------------- -------------- ---------------------------------- --------------------------------- ----------------------------------------------- ----- ------- ----- -------
  Total                   506            100.0                              301                               100.0                                           259   100.0   201   100.0
  Gender                                                                                                                                                                          
  Male                    415            82.0                               236                               78.4                                            205   79.2    154   76.6
  Female                  91             18.0                               65                                21.6                                            54    20.8    47    23.4
  Age                                                                                                                                                                             
  \<60                    215            42.5                               121                               40.2                                            117   45.2    89    44.3
  ≥60                     291            57.5                               180                               59.8                                            142   54.8    112   55.7
  Tumor site                                                                                                                                                                      
  Upper                   29             5.7                                20                                6.6                                             15    5.8     14    7.0
  Middle                  238            47.0                               158                               52.5                                            124   47.9    106   52.7
  Low                     239            47.2                               123                               40.9                                            120   46.3    81    40.3
  Differentiation                                                                                                                                                                 
  Well                    21             4.2                                15                                5.0                                             13    5.0     12    6.0
  Moderate                282            55.7                               182                               60.5                                            149   57.5    123   61.2
  Poor                    203            40.1                               104                               34.6                                            97    37.5    66    32.8
  Clinical stage                                                                                                                                                                  
  I+II                    301            59.5                                                                                                                 201   77.6          
  III+IV                  205            40.5                                                                                                                 58    22.4          
  Invasive depth                                                                                                                                                                  
  I                       111            21.9                               106                               35.2                                            76    29.3    73    36.3
  II                      224            44.3                               126                               41.9                                            104   40.2    84    41.8
  III                     171            33.8                               69                                22.9                                            79    30.5    44    21.9
  Lymph node metastasis                                                                                                                                                           
  No                      262            51.8                               250                               83.1                                            178   68.7    177   88.1
  Yes                     244            48.2                               51                                16.9                                            81    31.3    24    11.9
  Distant metastasis                                                                                                                                                              
  No                      447            88.3                               275                               91.4                                            249   96.1    196   97.5
  Yes                     59             11.7                               26                                8.6                                             10    3.9     5     2.5
  Vessel involvement                                                                                                                                                              
  No                      396            78.3                               268                               89.0                                            209   80.7    177   88.1
  Yes                     110            21.7                               33                                11.0                                            50    19.3    24    11.9
  Nerve involvement                                                                                                                                                               
  No                      323            63.8                               226                               75.1                                            183   70.7    152   75.6
  Yes                     183            36.2                               75                                24.9                                            76    29.3    49    24.4
  Necrosis                                                                                                                                                                        
  No                      353            69.8                               225                               74.8                                            185   71.4    152   75.6
  Yes                     153            30.2                               76                                25.2                                            74    28.6    49    24.4
  Smoking                                                                                                                                                                         
  No                      309            61.1                               202                               67.1                                            165   63.7    136   67.7
  Yes                     197            38.9                               99                                32.9                                            94    36.3    65    32.3
  FGFR1 amplification                                                                                                                                                             
  High                    44             8.7                                20                                6.6                                             20    7.7     10    5.0
  Low                     18             3.6                                8                                 2.7                                             9     3.5     7     3.5
  Disomy                  444            87.7                               273                               90.7                                            230   88.8    184   91.5

Invasive depth I, tumors had invaded to the mucous layer or submucosa; II, to the muscularis propria; III, to or beyond the adventitia.

*FGFR1* amplification status and clinicopathological features {#s2_2}
-------------------------------------------------------------

Based on a previous study \[[@R30]\], patients were classified into three groups by using prespecified criteria for the *FGFR1* gene copy number and *FGFR1*/ centromere 8 (CEN8) ratio. Among a total of 506 patients, 44 (8.7%) were high *FGFR1* amplification, 18 (3.6%) were low *FGFR1* amplification, and 444 (87.7%) were disomy (Figure [2](#F2){ref-type="fig"}; Table [1](#T1){ref-type="table"}). The median *FGFR1* gene copy number per nucleus and the mean *FGFR1*/CEN8 ratio in all patients were 2.45 (range, 0 to 12.25 copies per nucleus) and 1.21 (range, 0 to 4.64). The median *FGFR1* gene copy number was 6.57 (range, 3.19 to 12.25) in high amplification, 3.91 (range, 3.33 to 5.92) in low amplification, and 1.98 (range 0 to 4.20) in disomy group. The mean *FGFR1*/ CEN8 ratio was 3.75 (range 0.89 to 4.64), 1.49 (range, 1.12 to 1.90), and 0.95 (range, 0 to 1.75) in high, low and disomy group, respectively. Of 44 high *FGFR1* amplified tumors, 5 cases (11.4%) only satisfied the criterion of *FGFR1*/ CEN8 ratio is ≥ 2.0, 7 cases (15.9%) only satisfied the criterion of an average number of *FGFR1* signal per nucleus ≥6.0, and 26 cases (59.1%) only satisfied the criterion of percentage of tumor cells containing ≥ 15 *FGFR1* signals or large clusters in ≥ 10% cells. And only one case (2.3%) satisfied the criteria of *FGFR1*/CEN8 ratio is ≥ 2.0 and an average number of *FGFR1* signal per nucleus ≥6.0. Five cases (11.4%) satisfied all three criteria for *FGFR1* amplification.

![Fibroblast growth factor receptor 1 (*FGFR1*) amplification assessed by fluorescent in situ hybridization and the corresponding hematoxylin-eosin (HE) staining\
The *FGFR1* gene was labeled in red and the CEN8 reference probe in green. **(A)** high *FGFR1* amplification; **(B)** low *FGFR1* amplification; **(C)** disomy; **(D)** the corresponding HE staining of high *FGFR1* amplification; **(E)** the corresponding HE staining of low *FGFR1* amplification; **(F)** the corresponding HE staining of disomy.](oncotarget-08-74539-g002){#F2}

Associations between *FGFR1* amplification and clinicopathological characteristics for the 506 patients were shown in Table [2](#T2){ref-type="table"}. *FGFR1* amplification status correlated with clinical stage (*P*=0.047), lymph node metastasis (*P*=0.032), and necrosis (*P*=0.008). And high FGFR1 amplification is positively correlated with advanced stage, positive lymph node metastasis, and necrosis. There was no significant difference between the *FGFR1*^*high*^ and *FGFR1*^*low/disomy*^ group regarding gender, age, tumor site, invasive depth, distant metastasis, differentiation, vessel involvement, nerve involvement, and smoking.

###### Association between FGFR1-FISH results and the clinicopathlolgical characteristics in the cohort of 506 ESCC patients.

                          FGFR1-FISH results                        
  ----------------------- -------------------- ------ ----- ------- ---------
  Total                   44                   8.7    462   91.3    
  Gender                                                            0.432
   Male                   38                   9.2    377   90.8    
   Female                 6                    6.6    85    93.4    
  Age                                                               0.677
   \<60                   20                   9.3    195   90.7    
   ≥60                    24                   8.2    267   91.8    
  Tumor site                                                        0.939
   Upper                  2                    6.9    27    93.1    
   Middle                 21                   8.8    217   91.2    
   Low                    21                   8.8    218   91.2    
  Differentiation                                                   0.178
   Well                   0                    0      21    100.0   
   Moderate               22                   7.8    260   92.2    
   Poor                   22                   10.8   181   89.2    
  Clinical stage                                                    0.047\*
   I+II                   20                   6.6    281   93.4    
   III+IV                 24                   11.7   181   88.3    
  Invasive depth                                                    0.167
   I                      6                    5.4    105   94.6    
   II                     18                   8.0    206   92.0    
   III                    20                   11.7   151   88.3    
  Lymph node metastasis                                             0.032\*
   No                     16                   6.1    246   93.9    
   Yes                    28                   11.5   216   88.5    
  Distant metastasis                                                0.358
   No                     37                   8.3    410   91.7    
   Yes                    7                    11.9   52    88.1    
  Vessel involvement                                                0.352
   No                     32                   8.1    364   91.9    
   Yes                    12                   10.9   98    89.1    
  Nerve involvement                                                 0.180
   No                     24                   7.4    299   92.6    
   Yes                    20                   10.9   163   89.1    
  Necrosis                                                          0.008\*
   No                     23                   6.5    330   93.5    
   Yes                    21                   13.7   132   86.3    
  Smoking                                                           0.491
   No                     29                   9.4    280   90.6    
   Yes                    15                   7.6    182   92.4    

Invasive depth I, tumors had invaded to the mucous layer or submucosa; II, to the muscularis propria; III, to or beyond the adventitia.

\*P-value derived from χ^2^test.

Survival outcomes in the cohort of ESCC patients {#s2_3}
------------------------------------------------

With a median follow-up time of 35 months (range 2-102 months), the 5-year DFS and OS rate for all patients were 44.6 % and 45%. Mean and median times to DFS were 55.5 and 36.0months. Mean and median times to OS were 59.2 and 42.0 months. The 5-year DFS rate according to clinical stages were 60.9% in stage I-II, and 20.3% in stage III-IV patients. The 5-year OS rate was 61.1% for stage I-II, and 21.0% for stage III-IV patients.

Kaplan-Meier curves with a log rank test for DFS and OS were undertaken to assess the possible association between ESCC *FGFR1* amplification and patient survival. As shown in Figure [3A](#F3){ref-type="fig"} and [3B](#F3){ref-type="fig"}, the estimated mean DFS times and OS times were not significantly different in three *FGFR1* groups, which was consistent with a previous report \[[@R27]\]. As the low amplification group has a better DFS and OS trend (DFS, *P*=0.118; OS, *P*=0.122) than *FGFR1*^*high*^ group and has no statistical difference (DFS, *P*=0.521; OS, *P*=0.504) with the disomy group, we categorized total patients into *FGFR1*^*high*^ group and *FGFR1*^*low/disomy*^ group. Then we assessed the survival outcomes of these two groups, *FGFR1*^*high*^ group did not represent a statistically significant adverse prognosis than *FGFR1*^*low/disomy*^ group, which is different from the former research \[[@R24]\] (Figure [3C](#F3){ref-type="fig"} and [3D](#F3){ref-type="fig"}).

![Survival analysis on the cohort of ESCC patients, on the basis of clinical stage, and on the basis of DFS time 30 months as a group-dividing value\
To the whole cohort of patients, the *FGFR1* amplification status has no correlation with DFS and OS time no matter in three groups or in two groups **(A, B, C, and D)**. In patients with stage I-II, *FGFR1*^*high*^ was associated with adverse DFS and OS (**E and F**; *P*=0.019 or 0.034). In DFS≥30 months group, *FGFR1*^high^ did represent poor DFS and OS (**K and L**; *P*=0.009 or 0.007). However, in patients with stage III-IV disease or DFS\<30 months group, high *FGFR1* amplification was not associated with DFS and OS (**G, H, I and J**; *P*=0.298, 0.367, 0.964 or 0.912).](oncotarget-08-74539-g003){#F3}

The result of univariate analysis revealed that both DFS and OS were significantly associated with clinical stage (*P*\<0.001), lymph node metastasis (*P*\<0.001), distant metastasis (*P*\<0.001), vessel involvement (*P*=0.002), and nerve involvement (DFS, *P*=0.002; OS, *P*\<0.001). Upon multivariate analysis, both DFS and OS were associated with clinical stage (DFS, *P*=0.001; OS, *P*=0.003), lymph node metastasis (DFS, *P*=0.013; OS, *P*=0.009), and distant metastasis (*P*\<0.001). However, no matter in univariate or multivariate analysis, *FGFR1* amplification status is not a prognostic factor concerning to DFS and OS ([Supplementary Table 1](#SD2){ref-type="supplementary-material"}).

Survival outcomes based on clinical stage {#s2_4}
-----------------------------------------

To the stage I-II group, the estimated mean DFS time of the *FGFR1*^*high*^ group was significantly shorter compared with that of the *FGFR1*^*low/disomy*^ group (41.35±6.58 and 71.45±2.42 *P*=0.019, Figure [3E](#F3){ref-type="fig"}). Meanwhile, the estimated mean OS time was 47.59±5.56 and 74.10±2.27 months for patients with *FGFR1*^*high*^ and *FGFR1*^*low/disomy*^ tumors (*P*=0.034, Figure [3F](#F3){ref-type="fig"}). As to the stage III-IV patients, 5-year DFS and OS rate had no significant difference between *FGFR1*^*high*^ and *FGFR1*^*low/disomy*^ group. Conversely, *FGFR1*^*high*^ group showed a little better survival rate than *FGFR1*^*low/disomy*^ group (Figure [3G](#F3){ref-type="fig"} and [3F](#F3){ref-type="fig"}).

The univariate analysis revealed that patients with *FGFR1*^*high*^ had a significantly adverse DFS and OS rate (DFS, *P*=0.023; OS, *P*=0.039) than patients with *FGFR1*^*low/disomy*^ in stage I-II patients other than in stage III-IV patients. In addition, both DFS and OS were significantly associated with lymph node metastasis (*P*\<0.001) and distant metastasis (*P*\<0.001) in stage I-II patients and III-IV patients (Table [3](#T3){ref-type="table"} and [Supplementary Table 2](#SD3){ref-type="supplementary-material"}). However, the multivariate analysis revealed that the *FGFR1*^*high*^ is not a significant independent adverse factor for DFS and OS in stage I-II patients and III-IV patients (Table [3](#T3){ref-type="table"} and [Supplementary Table 2](#SD3){ref-type="supplementary-material"}).

###### Association between clinicopathological characteristics and DFS/OS by COX regression model analysis in ESCC patients with stage I and II disease.

                              DFS     OS                                                                                                                   
  --------------------------- ------- ------------- ----------- ------- ------------- ----------- ------- ------------- ----------- ------- -------------- -----------
  Gender                                                                                                                                                   
   Male                       1                                 1                                 1                                 1                      
   Female                     0.964   0.622-1.492   0.868       1.190   0.762-1.861   0.445       0.982   0.629-1.534   0.936       1.214   0.770-1.913    0.403
  Age                                                                                                                                                      
   \<60                       1                                                                   1                                                        
   ≥60                        1.068   0.735-1.551   0.729                                         1.047   0.715-1.531   0.814                              
  Tumor site                                                                                                                                               
   Upper/middle               1                                                                   1                                                        
   Low                        0.920   0.631-1.340   0.663                                         0.930   0.632-1.369   0.712                              
  Smoking                                                                                                                                                  
   No                         1                                                                   1                                                        
   Yes                        0.944   0.637-1.401   0.776                                         1.007   0.676-1.499   0.973                              
  Necrosis                                                                                                                                                 
   No                         1                                                                   1                                                        
   Yes                        1.119   0.738-1.697   0.597                                         1.118   0.728-1.717   0.611                              
  Differentiation                                                                                                                                          
  Well/Moderate               1                                 1                                 1                                 1                      
  Poor                        1.288   0.885-1.873   0.186       1.029   0.698-1.517   0.886       1.176   0.799-1.732   0.410       0.873   0.582-1.311    0.513
  Invasion depth                                                                                                                                           
   I+II                       1                                 1                                 1                                 1                      
   III                        0.987   0.637-1.527   0.952       1.560   0.933-2.609   0.090       1.073   0.691-1.666   0.753       1.686   0.996-2.855    0.052
  Lymph node metastasis                                                                                                                                    
   No                         1                                 1                                 1                                 1                      
   Yes                        2.474   1.649-3.711   \<0.001\*   2.469   1.565-3.895   \<0.001\*   2.694   1.790-4.057   \<0.001\*   2.899   1.824-4.606    \<0.001\*
  Distant metastasis                                                                                                                                       
   No                         1                                 1                                 1                                 1                      
   Yes                        6.275   3.996-9.854   \<0.001\*   6.131   3.769-9.971   \<0.001\*   6.162   3.911-9.708   \<0.001\*   6.389   3.884-10.509   \<0.001\*
  Vessel involvement                                                                                                                                       
   No                         1                                 1                                 1                                 1                      
   Yes                        1.159   0.674-1.995   0.594       0.825   0.474-1.436   0.497       1.133   0.647-1.985   0.662       0.812   0.459-1.438    0.475
  Nerve involvement                                                                                                                                        
   No                         1                                 1                                 1                                 1                      
   Yes                        1.046   0.686-1.593   0.835       1.180   0.737-1.889   0.491       1.172   0.767-1.791   0.464       1.396   0.862-2.261    0.175
  FGFR1 amplification                                                                                                                                      
   Disomy/Low amplification   1                                 1                                 1                                 1                      
   High amplification         2.001   1.099-3.644   0.023\*     1.646   0.900-3.008   0.106       1.933   1.035-3.610   0.039\*     1.544   0.823-2.896    0.176

Invasive depth I, tumors had invaded to the mucous layer or submucosa; II, to the muscularis propria; III, to or beyond the adventitia.

CI, confidence interval; HR, hazard ratio. ^\*^P\<0.05 indicated that the 95% CI of HR was not including 1.

Survival outcomes based on DFS time {#s2_5}
-----------------------------------

As DFS time is a valuable parameter in evaluating patients' health status after surgery and the impact of *FGFR1* amplification to DFS and OS showed a delayed trend, so we divided the whole cohort of ESCC patients into two groups according to different DFS times (24, 26, 28, 30, and 32 month respectively). After calculating these five different dividing months, we found that 30-month was the best dividing cutoff value ([Supplementary Table 3](#SD4){ref-type="supplementary-material"}). Therefore, the cohort of ESCC patients were divided into DFS\<30 months group and DFS≥30 months group.

The estimated mean DFS time of the *FGFR1*^*high*^ patients was significantly shorter compared with that of the *FGFR1*^*low/disomy*^ patients in DFS≥30 months group (72.80±6.90 and 91.74±1.58 months *P*=0.009, Figure [3K](#F3){ref-type="fig"}). In addition, the estimated mean OS time was 74.36±6.31 and 92.59±1.49 months for patients with *FGFR1*^*high*^ and *FGFR1*^*low/disomy*^ tumors in DFS≥30 months group (*P*=0.007, Figure [3L](#F3){ref-type="fig"}). No matter concerning to DFS or OS, there is no difference between *FGFR1*^*high*^ and *FGFR1*^*low/disomy*^ in DFS\<30 months group (Figure [3I](#F3){ref-type="fig"} and [3J](#F3){ref-type="fig"}).

The univariate analysis revealed that patients with *FGFR1*^*high*^ had a significantly adverse DFS and OS rate (DFS, *P*=0.013; OS, *P*=0.010) than patients with *FGFR1*^*low/disomy*^ in DFS≥30 months group other than in DFS\<30 months group (Table [4](#T4){ref-type="table"} and [Supplementary Table 4](#SD5){ref-type="supplementary-material"}). In addition, both DFS and OS were significantly associated with lymph node metastasis (*P*\<0.001), distant metastasis (*P*\<0.001), and vessel involvement (*P*\<0.001) in DFS≥30 months group (Table [4](#T4){ref-type="table"}). However, the multivariate analysis revealed that a *FGFR1*^*high*^ is not a significant independent adverse factor for DFS and OS in DFS\<30 months group and DFS≥30 months group (Table [4](#T4){ref-type="table"} and [Supplementary Table 4](#SD5){ref-type="supplementary-material"}).

###### Association between clinicopathological characteristics and DFS/OS by COX regression model analysis in ESCC patients with DFS≥30 months.

                              DFS      OS                                                                                                                        
  --------------------------- -------- -------------- ----------- -------- -------------- ----------- -------- -------------- ----------- ------- -------------- -----------
  Gender                                                                                                                                                         
   Male                       1                                   1                                   1                                   1                      
   Female                     1.352    0.682-2.683    0.388       1.664    0.818-3.384    0.160       1.308    0.641-2.668    0.461       1.626   0.776-3.404    0.198
  Age                                                                                                                                                            
   \<60                       1                                                                       1                                                          
   ≥60                        0.965    0.530-1.758    0.908                                           0.891    0.483-1.645    0.713                              
  Tumor site                                                                                                                                                     
   Upper/middle               1                                                                       1                                                          
   Low                        1.072    0.589-1.953    0.820                                           1.114    0.603-2.058    0.731                              
  Smoking                                                                                                                                                        
   No                         1                                                                       1                                                          
   Yes                        0.974    0.520-1.823    0.934                                           1.153    0.615-2.159    0.657                              
  Necrosis                                                                                                                                                       
   No                         1                                                                       1                                                          
   Yes                        1.261    0.657-2.423    0.486                                           1.434    0.742-2.772    0.284                              
  Differentiation                                                                                                                                                
   Well/Moderate              1                                   1                                   1                                   1                      
   Poor                       1.701    0.935-3.093    0.082       1.014    0.521-1.972    0.968       1.857    1.006-3.427    0.048\*     1.021   0.514-2.028    0.953
  Clinical stage                                                                                                                                                 
   I+II                       1                                   1                                   1                                   1                      
   III                        2.563    1.390-4.726    0.003\*     0.428    0.142-1.292    0.132       2.739    1.471-5.100    0.001\*     0.529   0.178-1.574    0.253
  Invasion depth                                                                                                                                                 
   I+II                       1                                   1                                   1                                   1                      
   III+IV                     1.031    0.545-1.953    0.925       1.148    0.471-2.802    0.761       0.928    0.480-1.792    0.823       0.814   0.320-2.071    0.665
  Lymph node metastasis                                                                                                                                          
   No                         1                                   1                                   1                                   1                      
   Yes                        3.109    1.702-5.678    \<0.001\*   3.304    1.293-8.441    0.013\*     3.400    1.826-6.331    \<0.001\*   3.053   1.193-7.815    0.020\*
  Distant metastasis                                                                                                                                             
   No                         1                                   1                                   1                                   1                      
   Yes                        12.682   6.145-26.174   \<0.001\*   11.347   4.390-29.329   \<0.001\*   10.692   5.166-22.127   \<0.001\*   7.802   3.077-19.781   \<0.001\*
  Vessel involvement                                                                                                                                             
   No                         1                                   1                                   1                                   1                      
   Yes                        3.088    1.675-5.693    \<0.001\*   1.999    0.973-4.107    0.059       3.559    1.919-6.599    \<0.001\*   2.389   1.157-4.934    0.019\*
  Nerve involvement                                                                                                                                              
   No                         1                                   1                                   1                                   1                      
   Yes                        1.221    0.645-2.312    0.540       1.393    0.638-3.044    0.405       1.306    0.685-2.490    0.418       1.627   0.721-3.670    0.241
  FGFR1 amplification                                                                                                                                            
   Disomy/Low amplification   1                                   1                                   1                                   1                      
   High amplification         2.789    1.239-6.276    0.013\*     1.490    0.614-3.620    0.378       2.896    1.283-6.536    0.010\*     1.515   0.620-3.705    0.362

Invasive depth I, tumors had invaded to the mucous layer or submucosa; II, to the muscularis propria; III, to or beyond the adventitia.

CI, confidence interval; HR, hazard ratio. ^\*^P\<0.05 indicated that the 95% CI of HR was not including 1.

Survival outcomes based on clinical stage and DFS time {#s2_6}
------------------------------------------------------

We combined the clinical stage and DFS 30-month to divide the whole cohort of ESCC patients into 4 groups. To the subset of patients whose DFS≥30 months in stage I-II, *FGFR1*^*high*^ showed a significant adverse influence to both DFS and OS (*P*=0.002 and *P*=0.003, Figure [4B](#F4){ref-type="fig"} and [4F](#F4){ref-type="fig"}). And there was no difference between *FGFR1*^*high*^ and *FGFR1*^*low/disomy*^ groups in other three subsets (Figure [4A, 4C-4E, 4G-4H](#F4){ref-type="fig"}).

![Survival analyses based on clinical stage and DFS time 30 months of ESCC patients\
In stage I-II patients with DFS time≥30 months, high *FGFR1* amplification was associated with adverse DFS and OS (**B and F**; *P*=0.002 or 0.001), but not in other three groups which are stage I-II with DFS\<30 months, stage III-IV with DFS\<30 months, and stage III-IV with DFS≥30 months (DFS: **A, C and D**; *P*=0.756, 0.733 or 0.942; OS: **E, G and H**; *P*=0.535, 0.600 or 0.997).](oncotarget-08-74539-g004){#F4}

To the subset of patients whose DFS time≥30 months in stage I-II, the results of the univariate analysis revealed that *FGFR1*^*high*^ group had a significantly shorter DFS and OS time (DFS, *P*=0.006; OS, *P*=0.003) than patients with *FGFR1*^*low/disomy*^ (Table [5](#T5){ref-type="table"}). In addition, both DFS and OS were significantly associated with lymph node metastasis (DFS, *P*=0.002; OS, *P*=0.001) and distant metastasis (*P*\<0.001, Table [5](#T5){ref-type="table"}). The multivariate analysis showed that *FGFR1*^*high*^ was significantly associated with a shorter OS (*P*=0.037, Table [5](#T5){ref-type="table"}). However, there was no trend toward worse DFS for *FGFR1*^*high*^ comparing to *FGFR1*^*low/disomy*^ in multivariate analysis (*P*=0.123, Table [5](#T5){ref-type="table"})

###### Association between clinicopathological characteristics and DFS/OS by COX regression model analysis in ESCC patients with DFS≥30 months in stage I and II.

                              DFS      OS                                                                                                                          
  --------------------------- -------- -------------- ----------- -------- --------------- ----------- -------- -------------- ----------- -------- -------------- -----------
  Gender                                                                                                                                                           
   Male                       1                                   1                                    1                                   1                       
   Female                     1.536    0.668-3.533    0.313       2.498    1.017-6.136     0.046\*     1.795    0.768-4.194    0.177       2.859    1.131-7.227    0.026\*
  Age                                                                                                                                                              
   \<60                       1                                                                        1                                                           
   ≥60                        0.663    0.307-1.434    0.297                                            0.559    0.248-1.259    0.161                               
  Tumor site                                                                                                                                                       
   Upper/middle               1                                                                        1                                                           
   Low                        0.830    0.370-1.864    0.653                                            0.833    0.356-1.947    0.673                               
  Smoking                                                                                                                                                          
   No                         1                                                                        1                                                           
   Yes                        0.637    0.256-1.587    0.333                                            0.688    0.273-1.732    0.427                               
  Necrosis                                                                                                                                                         
   No                         1                                                                        1                                                           
   Yes                        0.840    0.316-2.231    0.726                                            0.989    0.369-2.653    0.983                               
  Differentiation                                                                                                                                                  
   Well/Moderate              1                                   1                                    1                                   1                       
   Poor                       1.345    0.610-2.965    0.462       1.032    0.442-2.409     0.942       1.273    0.557-2.909    0.567       0.785    0.304-1.888    0.552
  Invasion depth                                                                                                                                                   
   I+II                       1                                   1                                    1                                   1                       
   III                        0.784    0.295-2.081    0.625       1.080    0.313-3.728     0.904       0.819    0.306-2.194    0.691       0.885    0.242-3.234    0.854
  Lymph node metastasis                                                                                                                                            
   No                         1                                   1                                    1                                   1                       
   Yes                        3.635    1.580-8.366    0.002\*     5.211    1.896-14.317    0.001\*     4.021    1.720-9.401    0.001\*     5.164    1.878-14.195   0.001\*
  Distant metastasis                                                                                                                                               
   No                         1                                   1                                    1                                   1                       
   Yes                        19.124   7.023-52.075   \<0.001\*   30.942   9.189-104.191   \<0.001\*   14.484   5.255-39.919   \<0.001\*   20.623   6.180-68.817   \<0.001\*
  Vessel involvement                                                                                                                                               
   No                         1                                   1                                    1                                   1                       
   Yes                        2.432    0.976-6.059    0.056       2.154    0.777-5.973     0.140       2.608    1.035-6.547    0.042\*     2.343    0.863-6.363    0.095
  Nerve involvement                                                                                                                                                
   No                         1                                   1                                    1                                   1                       
   Yes                        1.234    0.518-2.938    0.635       1.885    0.629-5.646     0.258       1.424    0.590-3.435    0.431       2.653    0.823-8.557    0.102
  FGFR1 amplification                                                                                                                                              
   Disomy/Low amplification   1                                   1                                    1                                   1                       
   High amplification         4.521    1.549-13.195   0.006\*     2.430    0.786-7.514     0.123       5.180    1.766-15.194   0.003\*     3.239    1.076-9.746    0.037\*

Invasive depth I, tumors had invaded to the mucous layer or submucosa; II, to the muscularis propria; III, to or beyond the adventitia.

CI, confidence interval; HR, hazard ratio. ^\*^P\<0.05 indicated that the 95% CI of HR was not including 1.

DISCUSSION {#s3}
==========

The poor prognosis of ESCC highlights the need for new prognostic markers in this disease and an improved understanding of the key genetic and progression are critical for the development of effective therapeutics.

In the present study, we investigated whether high *FGFR1* amplification was associated with the clinicopathological parameters and its impact on survival in patients with operable ESCC. Our study demonstrated that high *FGFR1* amplification is not a common genetic alteration (8.7%) but presented as a delayed adverse prognostic factor in resected stage I-II ESCC patients. To the best of our knowledge, this is the first report analyzing the prognosis impact of *FGFR1* amplification by linking it to clinical stage and DFS time. This information could have clinical value in identifying ESCC patients who are at high risk of progression and may benefit the most from FGFR-inhibiting drugs.

The prevalence of *FGFR1* amplification is the firstly determining factor in judging whether FGFR inhibitors could be used in ESCC patients. Different from a singular criterion only using *FGFR1* copy numbers, we chose a more sophisticated *FGFR1* FISH criterion considering gene copy number per nucleus, *FGFR1*/CEN8 ratio, and percentage of gene clusters at the same time \[[@R30]\]. Among those patients, 8.7% were high *FGFR1* amplification, 3.6% were low *FGFR1* amplification, and 87.7% were disomy. The *FGFR1* amplification rate (12.3%) of our study, as determined by FISH analysis, was comparable to previous reports, ranging from 6% to 9.7%\[[@R27]-[@R29]\]. Given the relatively specific *FGFR1* amplification, it may represent a potential therapeutic target for ESCC.

Recently, genome-wide comprehensive analysis found considerable overlap between the genes that are frequently mutated in ESCC and other types of squamous cell carcinoma \[[@R6], [@R7]\]. *FGFR1* amplification has been reported in numerous kinds of tumors, especially in squamous cell lung cancer \[[@R13], [@R20]\] and head and neck squamous cell carcinoma \[[@R22]\]. However, when considering the prognostic value of *FGFR1* amplification, the results are controversial. In resected squamous cell lung cancer, one study found that no significant difference in OS by *FGFR1* amplification status no matter in the whole research group or in advanced stage subset \[[@R31]\]. In another study, *FGFR1* amplification is an independent negative prognostic factor in surgically resected squamous cell lung cancer \[[@R19]\]. And the prognostic value is not consistent in ESCC between different groups as whether high *FGFR1* amplification is an independent poor prognostic factor or no association between *FGFR1* amplification status and clinical outcome \[[@R27], [@R28]\]. This is may be due to different races and different criteria.

In our study, we evaluate the estimated mean DFS times and OS times in three *FGFR1* groups (high amplification, low *FGFR1* amplification and disomy), and the DFS and OS time has no significant difference which is consistent with Kim's report \[[@R27]\]. Due to the similar survival outcome between low and no *FGFR1* amplification group, we categorized total patients into *FGFR1*^*high*^ group and *FGFR1*^*low/disomy*^ group and assessed the survival outcomes of these two groups. *FGFR1*^*high*^ did not represent a statistically significant adverse prognosis, which is different from the previous report \[[@R27]\], and this is may be owing to the tumor heterogeneity of different research groups from different countries.

As clinical stage is an important clinicopathological feature, the prognosis usually vary in patients with different stages. To squamous cell lung cancer, the *FGFR1* amplification is an independent adverse prognostic marker in early stage patients \[[@R32]\], and another study found that no significant difference in OS by *FGFR1* amplification status in advanced stage subset \[[@R31]\]. We then categorized the patients into stage I-II group and stage III-IV group. To the stage I-II group, the estimated mean DFS and OS time of the *FGFR1*^*high*^ group was significantly shorter compared with that of the *FGFR1*^*low/disomy*^ group. Interesting, the trend is only can be detected in stage I-II group other than stage III-IV group, implying that high *FGFR1* amplification prognostic value is relying on clinical stage. The result is confirmed by univariate COX regression analysis.

DFS time is measured from the time of surgery to initial tumor relapse (local recurrence or distant) or death as a result of any cause and is an important index for surgeon to follow up. Moreover, DFS is also served as the endpoint of the phase III clinical trials of antitumor drugs. When we divided the whole group into two subsets according to the DFS time (30-month), the estimated mean DFS and OS time of the *FGFR1*^*high*^ patients was significantly shorter compared with that of the *FGFR1*^*low/disomy*^ patients in DFS≥30 months group. Clearly, after the patient finished radical operation, if the patient can live without recurrence or distant metastasis for more than 30 months, the *FGFR1*^*high*^ status is important to the prognosis of the patient, indicating that high *FGFR1* amplification is a delayed prognostic factor which is just as same as the prognostic value of EGFR amplification in ESCC \[[@R33]\].

Aimed to find the most influenced subgroup patients by *FGFR1*^*high*^ status, we firstly combined the clinical stage and DFS 30-month to divide the whole cohort of ESCC patients. To the subset of patients whose DFS≥30 months in stage I-II, *FGFR1*^*high*^ showed a significant adverse influence to both DFS and OS. And there is no difference between *FGFR1*^*high*^ and *FGFR1*^*low/disomy*^ groups in other three subsets. By this way, we precisely selected the most influenced patients by *FGFR1*^*high*^ status.

*FGFR1* amplification is one of the most promising findings in ESCC due to the availability of FGFR inhibitors' application. Several small molecules, such AZD4547 and PD173073, targeting the *FGFR1* tyrosine kinase are now in clinical trials for the treatment of patients with squamous cell lung cancer and other solid malignant tumors \[[@R13], [@R34]\]. And *FGFR1* amplification is the most important inclusion criterion. Our study precisely stratified the patients according to clinical stage and DFS time, finding out the subgroup patients whose prognosis were most decreased by high *FGFR1* amplification and this may be important in the future for selecting patients enrolled in clinical trials, providing a theoretical basis in patient selection.

In conclusion, we demonstrated that *FGFR1* amplification was an infrequent genetic alteration, and for firstly, we found high *FGFR1* amplification was an independent delayed adverse prognostic factor only in stage I-II ESCC patients, suggesting that FGFR amplification may be a viable prognostic factor in these patients.

MATERIALS AND METHODS {#s4}
=====================

Patients and tissue samples {#s4_1}
---------------------------

The study was conducted in a cohort of patients with ESCC who underwent surgical resection in our institution from 2007 to 2010. Two pathologists confirmed the diagnosis of ESCC by hematoxylin-eosin (HE) staining. A predesigned data collection format was used to review the patients' medical records for evaluation of clinicopathological characteristics and survival outcomes. We identified 592 patients. Of those we excluded patients with very limited tumor tissue, patients with neoadjuvant therapy, and patients with incomplete clinicopathological information or survival information (n=49). Paraffin-embedded (FFPE) tumor specimens were used to construct a tissue microarray (TMA) \[[@R35]\] and then performed HE staining to estimate the tumor ratio of each core. A total of 37 patients were excluded because of limited tumor tissue (less than 100 tumor nuclei) in TMA (Figure [1](#F1){ref-type="fig"}, Table [1](#T1){ref-type="table"}). Eventually, the tumor samples of 506 patients were available for examination of *FGFR1* amplification. Each patient provided informed consent for the use of their tissue samples and the study was approved by the institutional review board of Zhongshan Hospital.

*FGFR1* fluorescence in situ hybridization {#s4_2}
------------------------------------------

Fluorescent in situ hybridization (FISH) assay was performed on the tissue microarrays by using *FGFR1* probe that hybridizes to the band 8p12 with Spectrum Red and CEP 8 with SpectrumAqua Probe RUO (green) (Abbott Molecular, Abbott Park, IL) following routine methods. Two experienced evaluators blinded to the clinical data interpreted FISH analyses. At least 100 nuclei per patient were evaluated. The prespecified threshold for assigning a sample to the *FGFR1*^*high*^ group was an *FGFR1*/CEN8 ratio is ≥ 2.0, or average number of *FGFR1* signals/ tumor cell nucleus ≥ 6.0, or percentage of tumor cells containing ≥ 15 *FGFR1* signals or large cluster in ≥ 10%. Percentage of tumor cells containing ≥ 5 *FGFR1* signals in ≥ 50% was defined as low amplification, and a copy number of two was considered disomy \[[@R30]\].

Statistical analysis {#s4_3}
--------------------

The primary end point was to assess whether *FGFR1* amplification affected survival in terms of DFS and OS in patients with resected ESCC. DFS was measured from the time of surgery to initial tumor relapse (local recurrence or distant) or death as a result of any cause. OS, calculated from the time of surgery to death or last follow-up date. Associations with clinical characteristics were evaluated by using Fisher's exact test or the χ^2^ test. Kaplan-Meier curves with log-rank tests were used to calculate the cumulative survival proportion for OS and DFS by *FGFR1* amplification level. A Cox proportional hazards model was applied to investigate the univariate and multivariate hazard ratios for the study variables. Multivariate analysis was performed for all the significant variables in the univariate analysis. Statistical significance was set at *P*\<0.05 for all analyses. All statistical analyses were performed by using SPSS version 22.0 (SPSS, Chicago, IL).

SUPPLEMENTARY MATERIALS TABLES {#s5}
==============================
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